INTRAVITREAL BEVACIZUMAB DURING PREGNANCY
- 1 October 2010
- journal article
- case report
- Published by Wolters Kluwer Health in Retina
- Vol. 30 (9) , 1405-1411
Abstract
To report the clinical course of four women treated with intravitreal bevacizumab during pregnancy. Observational case series. Four pregnant women were treated with intravitreal bevacizumab for choroidal neovascularization (CNV) because of presumed ocular histoplasmosis syndrome punctate inner choroidopathy, or sarcoid uveitis. Patients received a mean of 2.6 ± 2.3 injections (range, 1-6 injections) while pregnant. One patient was treated with five additional injections while breastfeeding. The mean follow-up duration after the most recent injection was 14 ± 2.9 months (range, 11-18 months). Snellen visual acuity improved in all 4 patients with a mean of 5.75 ± 2.2 lines (range, 3-8 lines). At the most recent follow-up, all patients had involuted CNV that did not require additional treatment. All patients had an uneventful prenatal course and delivered healthy full-term infants. All children have remained healthy, exhibiting normal development and growth during infancy. Offering pregnant patients intravitreal bevacizumab therapy during pregnancy for off-label ocular indications can result in significant visual improvement. No adverse events related to treatment occurred in any patient included in this study. Additional studies with more patients and longer follow-up duration are required to identify any risks associated with treatment.Keywords
This publication has 34 references indexed in Scilit:
- Intravitreal bevacizumab (Avastin(R)) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trialBritish Journal of Ophthalmology, 2008
- Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaksEye, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Intravitreal Bevacizumab for Treatment of Uveitic Macular EdemaOphthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyOphthalmology, 2006
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Incidence of Early Loss of PregnancyNew England Journal of Medicine, 1988